Hjem
  • E-postAgnete.Engelsen@uib.no
  • Telefon+47 975 15 414
  • Besøksadresse
    Institutt for Biomedisin
    Jonas Lie vei 91
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Immunforsvarets frontliner

'I prinsippet kan immunsystemet vårt ta knekken på kreft. Men kreftcellene tyr til kamuflasje for å slippe unna'.

Les mer om forskningsprosjekt, metoder og samarbeidspartnere i denne Feltrapporten fra Institut Gustave Roussy (Paris, Frankrike) i Forskerforum. Artikkelen er skrevet av Kjerstin Gjengedal. 

On a quest to cure cancer

Intervju i the UiB Magazine om PhD arbeid og motivasjon (english only). By Jens Helleland Ådnanes. 

Les mer om min mulighet til å bli kjent med andre kreftforskere fra ulike kulturer og bli inspirert av noen av de fremste i verden gjennom deltagelse på på Harvard Medical School (HMS) prostgraduate medical education certificate program.

Kreftforskning krever et arsenal av metoder. Les mer om første heldigitale versjon av metodekurset for PhD studenter på CCBIO's Forskerskole i Kreft-studier, CCBIO905: Methods in Cancer Biomarker Research.

 

Stort engasjement på Forskningsdagene i Bergen

Begeistrede barn og voksne stod tett i tett da forskere ved Center for Cancer Biomarkers (CCBIO) viste de frammøtte levende kreftceller i mikroskopet og framførte skodespelet om kreftcella Fråtse-Frida på Forskingstorget.

Les mer om forskningsformidlingen til barn og unge i Studvest.

Digital undervisning: Les mer om første heldigitale versjon av PhD kurset CCBIO905: Methods in Cancer Biomarker Research

 

Kurs med emneansvar: 

CCBIO901 Junior Scientist Symposium, PhD kurs, The CCBIO Research School for Cancer Studies, UiB (RSCS)

MED1BIOMED Biomedisinske Tema, Obligatorisk for medisinstudenter, Institutt for Biomedisin, UiB 

CCBIO905 Methods in Cancer Biomarker Research, PhD kurs, The CCBIO Research School for Cancer Studies, UiB (RSCS)

HUCEL 320 Cell culture and cellular techniques: Flow Cytometry, Master kurs, Institutt for Biomedisin, UiB

 

Individuelle forelesninger: 

BMED331 Tumorbiologi,  Master kurs, Institutt for Biomedisin, UiB 

MED1BIOMED Biomedisinske Tema, Obligatorisk for medisinstudenter, Institutt for Biomedisin, UiB 

CCBIO905 Methods in Cancer Biomarker Research, PhD course, The CCBIO Research School for Cancer Studies, UiB (RSCS)

BZL 256 Embryologi, Institutt for Zoologi, UiB

MED1BAS, FARM 260/NUTR, ODONT, Histology, Labkurs, Institutt for Biomedisin, UiB

Vitenskapelig artikkel
  • 2020. AXL is a driver of stemness in normal mammary gland and breast cancer. iScience. 1-40.
  • 2020. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology. 973-999.
  • 2019. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism.
  • 2019. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. British Journal of Cancer. 545-555.
  • 2019. AXL targeting overcomes human lung cancer cell resistance to NK- And CTL-mediated cytotoxicity. Cancer immunology research. 1789-1802.
  • 2018. Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance. Frontiers in Cell and Developmental Biology.
  • 2018. Cancer Immunotherapy 2017 (Paris, France). Progress and challenges. Bulletin du Cancer. 537-541.
  • 2018. A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 57-70.
  • 2017. Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts. PLOS ONE. 1-19.
  • 2014. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells . Cancer Medicine. 812-824.
  • 2014. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. Journal of Immunology. 6192-6206.
  • 2011. Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma. PLOS ONE. 14 sider.
  • 2011. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathologica. 495-510.
  • 2010. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Research. 4274-4279.
  • 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 5331-5339.
  • 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • 2008. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. International Journal of Cancer. 761-768.
  • 2008. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. The FASEB Journal. 3120-3128.
  • 2006. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
Leserinnlegg
  • 2010. Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track - Letter. Cancer Research. 6393-6396.
Mastergradsoppgave
  • 2019. The Role of Axl in Cancer and Stem Cell Plasticity: in vivo Lineage Tracing and Imaging Mass Cytometry Analysis.
Doktorgradsavhandling
  • 2013. Intratumoural Heterogeneity of Glioblastoma. Implications of Immature Phenotypes on Tumour Growth and Resistance to Treatment.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • 2020. Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. 22 sider.
  • 2017. The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. 28 sider.
Sammendrag/abstract
  • 2010. NG2 PROMOTES RESISTANCE TO IONIZING RADIATION BY ELEVATED PEROXIREDOXIN-1 AND DNA DAMAGE RESPONSE IN GLIOBLASTOMA MULTIFORME. Neuro-Oncology. 8-8.
  • 2009. Targeting the tumor stroma: a novel therapeutic strategy based on separate analysis of the malignant and stromal cell compartments in brain tumors. Neuro-Oncology. 221-222.
  • 2009. CD133-NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE MARKERS DISPLAY TUMORIGENICITY IN VIVO. Neuro-Oncology. 917-917.
  • 2008. CD133-NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE MARKERS DISPLAY TUMORGENICITY IN VIVO. Neuro-Oncology. 778-778.
Vitenskapelig oversiktsartikkel/review
  • 2020. Hypoxia-driven intratumor heterogeneity and immune evasion. 1-10.
  • 2020. Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. 22 sider.
  • 2017. Adaptive mechanisms of resistance to anti-neoplastic agents. 53-66.

Se fullstendig oversikt over publikasjoner i CRIStin.

Forskergrupper

Twitter